# **Supplemental Online Content**

Martens KL, Li A, La J, et al. Epidemiology of cancer-associated venous thromboembolism in patients with solid and hematologic neoplasms in the Veterans Affairs Health Care System. *JAMA Netw Open.* 2023;6(6):e2317945. doi:10.1001/jamanetworkopen.2023.17945

**eMethods.** Data Extraction and Harmonization for the Veterans Affairs Healthcare System **eReferences.** 

- eTable 1. Systemic Therapy Classifications
- eTable 2. Cumulative Incidence of VTE at 6 and 12 Months by Diagnosis Year
- eTable 3. Cumulative Incidence of VTE at 1 Year by Cancer Type
- eTable 4. Cumulative Incidence of VTE at 1 Year by Cancer Stage
- eTable 5. Cumulative Incidence of VTE at 1 Year by Race and Ethnicity
- eTable 6. Multivariable Cox Regression Analysis for Association With Overall Mortality
- eFigure 1. Consort Diagram
- eFigure 2. Cumulative Incidence of VTE at 1 Year by Cancer Stage
- eFigure 3. Cumulative Incidence of VTE At 1 Year by Cancer Type and Race and Ethnicity

This supplemental material has been provided by the authors to give readers additional information about their work.

### eMethods. Data extraction and harmonization for the Veterans Affairs healthcare system

#### Data source and linkage

This study utilizes patient-level data from the Veterans Affairs (VA) healthcare system, which is the largest integrated healthcare system with 171 medical centers and 1,113 outpatient clinics for veterans in the United States (US).

Linkage at the patient level was achieved by matching unique identifiers between electronic health record data collated in the VA Corporate Data Warehouse (CDW) and national VA Cancer Registry data, which is also available in the CDW (oncology domain) from 2006-2021.

Data extracted from the VA Cancer Registry included cancer histology, American Joint Committee on Cancer (AJCC) staging, demographics, and mortality. Data extracted from the CDW included socioeconomic factors, clinical encounter, medical history, problem list, medication, International Classification of Diseases Clinical Modification (ICD-9-CM and ICD-10-CM) diagnosis and procedure codes, Current Procedural Terminology/Healthcare Common Procedure Coding System (CPT/HCPCS) procedure codes, discharge summary, clinic notes, and radiology reports.

#### **Cohort selection (eFigure 1)**

Cancer Registry exclusions required patients to have a first-ever histologically confirmed invasive cancer diagnosis. CDW exclusions required patients to be primary user, and not having had recent diagnosis of acute venous thromboembolism (VTE) in the preceding 180 days (eFigure 1).

## Index date and follow-up

Outcome was evaluated from the index date of histologic cancer diagnosis until first outcome event, death, loss of follow-up defined as a 90-day gap without any clinical encounters, or administrative censoring on 4/1/2022.

#### **Outcome variables**

<u>Primary outcome</u>: *overall VTE* was defined as a composite outcome of radiologically confirmed symptomatic or incidental pulmonary embolism (PE), proximal or distal lower extremity DVT (LE-DVT), or upper extremity catheter-related DVT (CR-DVT) after index date.

<u>Secondary outcome</u>: *PE/LE-DVT* was defined as an important subgroup of the primary outcome (excluding CR-DVT). Please refer to the online Data Supplement from our previous publication for detailed cohort definition and validation where the weighted sensitivity was 96% and weighted positive predicted value was 91% [1].

#### **Baseline variables**

## Cancer <u>site/histology</u> subtype:

Cancer site and histology were recoded from VA Cancer Registry at the time of diagnosis according to the SEER standard ICD-O-3 recode for common solid tumors and rare disease classification for hematologic malignancies and rare histology like leukemia, lymphoma, sarcoma and neuroendocrine [2, 3].

## Cancer Stage:

AJCC cancer staging (I, II, III, IV, unknown) at the time of cancer diagnosis was extracted from the VA Cancer Registry. Certain cancers had unknown stage when AJCC classification was not appropriate (e.g. brain cancer, leukemia, myeloma) for which SEER staging was used.

## <u>Treatment Regimen (supplemental Table 2):</u>

First-line systemic therapy extracted from the VA CDW and classified as chemotherapy, immune checkpoint inhibitor, target therapy, or endocrine therapy. See supplemental Table 2 for detailed breakdown by generic drug name.

#### Age:

Age in years was extracted directly from the CDW at the time of cancer diagnosis.

#### Sex:

Sex was extracted directly from the CDW at the time of cancer diagnosis.

#### Race/Ethnicity:

Race/ethnicity was extracted from the VA Cancer Registry and CDW (SPatient) and recoded as Non-Hispanic White, Non-Hispanic Black, Hispanic, Non-Hispanic Asian, Pacific Islander, Alaskan Natives, American Indian (altogether classified as API), or Other/Unknown.

### Region and Rurality:

Region and rurality were extracted directly from the CDW at the time of cancer diagnosis.

## National Area Deprivation Index (ADI) score:

To determine socioeconomic status, patients' home addresses were geocoded and linked to corresponding census block groups. These block groups were mapped to the area deprivation index (ADI), which is derived using 17 weighted indicators from US Census American Community Survey 5-year estimates (poverty, housing, employment, education) and divided into quartiles based on the national ADI scores distribution, with higher scores indicating more disadvantaged neighborhoods [4, 5].

## National Cancer Institute Comorbidity Index (NCI-CI):

Individual comorbidities, including history of paralysis, were determined from the NCI-CI within a 12-month lookback window before the diagnosis date using inpatient and outpatient facility coded diagnoses extracted from the VA CDW [6].

## History of PE/LE-DVT:

ICD codes for VTE any time prior to diagnosis were extracted from the VA CDW. These were not confirmed with chart review. Please refer to the online Data Supplement from our previous publication for exact codes and timing use [1].

## **Prolonged hospitalization:**

Prolonged hospitalization ≥3 days was extracted from the VA CDW prior to diagnosis within a 3-month lookback window.

## Anticoagulation/antiplatelet prescription:

Anticoagulation/antiplatelet prescription data was extracted from the VA CDW prior to diagnosis within a 6-month lookback window from the outpatient settings.

## Body Mass Index:

Data calculated from the VA CDW using any height and the closest weight prior to diagnosis within a 36-month lookback window.

#### White blood cell (WBC) count:

Data captured from the VA CDW using the closest WBC within a window between 3-month prior to 1-month after the diagnosis date. If multiple values were present, then the one closest to the index date was used.

#### Hemoglobin:

Data captured from the VA CDW using the closest hemoglobin within a window between 3-month prior to 1-month after the diagnosis date. If multiple values were present, then the one closest to the index date was used.

### Platelet count:

Data captured from the VA CDW using the closest platelet count within a window between 3-month prior to 1-month after the diagnosis date. If multiple values were present, then the one closest to the index date was used.

### Missing data

Missing data were classified as a categorical variable "NA" in our study, so the final multivariable model is run on the entire dataset without imputation or exclusion.

#### **eReferences**

- 1. Li A, La J, May SB, et al. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol. 2023 Jan 10:JCO2201542.
- 2. National Cancer Institute (NCI): Site Recode ICD-O-3/WHO 2008 Definition [Internet]. Survuillance, Epidemiol End Results Progr, 2021[cited 2023 Feb 1] Available from:https://seer.cancer.gov/siterecode/icdo3\_dwhoheme/index.html
- 3. National Cancer Institute (NCI): Rare Cancer Classification [Internet]. Survuillance, Epidemiol End Results Progr, 2021[cited 2023 Feb 1] Available from: <a href="https://seer.cancer.gov/seerstat/variables/seer/raresiterecode/">https://seer.cancer.gov/seerstat/variables/seer/raresiterecode/</a>
- 4. Singh, G.K. Area deprivation and widening inequalities in US mortality, 1969-1998. Am J Public Health, 2003. 93(7): p. 1137-43.
- 5. Kind, A.J.H. and W.R. Buckingham. *Making Neighborhood-Disadvantage Metrics Accessible The Neighborhood Atlas*. N Engl J Med 2018. 378(26): p. 2456-2458.
- 6. National Cancer Institute (NCI): NCI Comorbidity Index 2021 Version [Internet]. Div Cancer Control Popul Sci 2021; Available from: <a href="https://healthcaredelivery.cancer.gov/seermedicare/considerations/macro-2021.html">https://healthcaredelivery.cancer.gov/seermedicare/considerations/macro-2021.html</a>.

eTable 1. Systemic Therapy Classifications

eTable 1. Systemic Therapy C	Classifications
Drug name (generic)	Drug class (proposed)
abemaciclib	target
abiraterone	endo
acalabrutinib	target
ado-trastuzumab	target
afatinib	target
alectinib	target
alitretinoin	target
alpelisib	target
anastrozole	endo
arsenic	target
asparaginase	chemo
atezolizumab	immuno
avelumab	immuno
axitinib	target
azacitidine	chemo
bendamustine	chemo
bevacizumab	target
bexarotene	target
bicalutamide	endo
binimetinib	target
bleomycin	chemo
blinatumomab	target
bortezomib	target
bosutinib	target
brentuximab	target
cabazitaxel	chemo
cabozantinib	target
capecitabine	chemo
carboplatin	chemo
carfilzomib	target
carmustine	chemo
cemiplimab-rwlc	immuno
ceritinib	target
cetuximab	target
chlorambucil	chemo
cisplatin	chemo
cladribine	chemo
clofarabine	chemo
cobimetinib	target
crizotinib	target
cyclophosphamide	chemo
cytarabine	chemo
cytarabine/PF	chemo
dabrafenib	target
dacarbazine	chemo
dactinomycin	chemo
daratumumab	target
darolutamide	endo
dasatinib	target
daunorubicin	chemo
decitabine	chemo
decitabilie	CHCIHO

degaterix docetaxel chemo docorubicin chemo durvalumab immuno elotuzumab immuno elotuzumab itarget enasidenib target enasidenib target enzalutamide endo epirubicin chemo erdafitnib target eribulin chemo erlotinib target everolimus target fludarabine chemo fluorouracil chemo flutamide endo gemitabine chemo gemitabine chemo gemitabine chemo gemitabine chemo gemitabine chemo fluoroxyurea chemo idelalisib target ifosfamide chemo idelalisib target interferon target lapatinib target laroxicarant chemo ivosidenib target lapatinib target laroxicarant chemo ivosidenib target lerozole endo lomustine chemo ivosidenib target leroxole endo lomustine chemo indostaurin target mercaptopurine chemo methotrexate chemo mitoxantrone chemo mitoxantrone chemo nelarabine chemo nelarabine chemo neratinib target niraparib target niraparib	dagaraliy	endo
doxorubicin chemo durvalumab immuno elotuzumab target enasidenib target encorafenib target enzalutamide endo epirubicin chemo erdafitinib target etoposide chemo everolimus target exemestane endo fluorouracil chemo fluorouracil chemo gemitabine chemo gemitabine chemo gemitabine chemo gemitabine chemo ibrutinib target goserelin endo hydroxyurea chemo idalalisib target iinotuzumab target iinotuzumab target jiosfamide chemo iinotuzumab target jiosfamide chemo iinotuzumab target jiosfamide chemo iinotuzumab target jiosfamide chemo iinatinib target iinotuzumab target jiosfamide chemo iinatinib target iinotuzumab target jiosfamide chemo iinatinib target iinotuzumab target iinotecan chemo ivosidenib target lapatinib target lapatinib target lapatinib target lenalidomide target lenalidomide target lenalidomide endo lomustine chemo mototane chemo midostaurin target mitomycin chemo mitotane endo mitoxantrone chemo neratinib target nilotinib target nilotinib target nilotinib target	degarelix	
durvalumab elotuzumab target enasidenib target encorafenib enzalutamide epirubicin erdafitinib target eribulin chemo erlotinib target etoposide everolimus exemestane fludarabine fludarabine gemituzumab target goserelin hydroxyurea ibrutinib target iinotuzumab target iinotuzumab target iinotuzumab target iinotuzumab target iinotuzumab target ilapatinib target ilarget ilarg		
elotuzumab target enasidenib target encorafenib target enzalutamide endo epirubicin chemo erdafitinib target eribulin chemo erlotinib target etoposide chemo everolimus target exemestane endo fam-trastuzumab target fludarabine chemo fluorouracil chemo flutestrant endo gemitabine chemo gemituzumab target goserelin endo hydroxyurea chemo ibrutinib target ifosfamide chemo imatinib target interferon target irinotecan chemo ivosidenib target lapatinib target lenvatinib target mercaptopurine chemo methotrexate chemo midostaurin target mitomycin chemo methotrexate chemo mitotane endo mitoxantrone chemo nelarabine chemo nelarabine chemo neratinib target		
enasidenib target encorafenib endo epirubicin chemo erdafitinib target eribulin chemo erlotinib target etoposide chemo everolimus target exemestane endo fludarabine chemo fluorouracil chemo gemitabine chemo gemitabine chemo gemitabine chemo ibrutinib target idarubicin chemo imatinib target infortecan chemo ixazomib target interferon target interferon chemo ixazomib target lapatinib target letrozole endo lorlatinib target letrozole endo lorlatinib target letrozole endo lorlatinib target letrozole endo lorlatinib target letrozole chemo mitotane endo lorlatinib target letrozole endo lorlatinib target letrozole chemo midostaurin target mitorycane chemo lorlatinib target letrozole endo lorlatinib target mercaptopurine chemo midostaurin target mitotycane chemo midostaurin target mitomycin chemo mitotane endo mitoxantrone chemo mitoxantrone chemo miotarinib target mitorycin target mitorycin chemo mitotane endo mitoxantrone chemo neratinib target mitorycin chemo mitotane endo mitoxantrone chemo neratinib target mitorycin target mitomycin target nilotinib target nilotinib target mitorycin chemo metaspet nilotinib target		
encorafenib target enzalutamide endo epirubicin chemo erdafitinib target eribulin chemo erlotinib target etoposide chemo everolimus target exemestane endo fam-trastzumab target fludarabine chemo fluorouracil chemo gemitabine chemo gemitabine chemo gemitabine chemo ibrutinib target ifosfamide chemo imatinib target initerferon target irinotecan chemo ivosidenib target lapatinib target larotrectinib target lenalidomide endo lorlatinib target lenalidomide chemo imotoane chemo indonatore chemo indonatore chemo indonatore chemo indonatore chemo ixazomib target lenalidomide chemo ixazomib target lenvatinib target		
enzalutamide endo epirubicin chemo erdafitinib target eribulin chemo erlotinib target etoposide chemo everolimus target exemestane endo fam-trastuzumab target fludarabine chemo fluorouracil chemo flutamide endo gemcitabine chemo gemtuzumab target goserelin endo hydroxyurea chemo ibrutinib target iidarubicin chemo imatinib target iinotuzumab target iinotuzumab target jfosfamide chemo iimatinib target iinotuzumab target iinotecan chemo iivosidenib target iixabepilone chemo iixazomib target lapatinib target lapatinib target letrozole endo leuprolide endo lomustine chemo modostaurin target mitomycin chemo midostaurin chemo midostaurin target mitomycin chemo meratinib target milotinib target nilotinib target		<del>- i</del>
epirubicin erdafitinib target eribulin chemo erlotinib target etoposide chemo everolimus target exemestane endo fam-trastuzumab target fludarabine fluorouracil flutamide endo gemcitabine gemcitabine gemcitabine dhydroxyurea ibrutinib tidarubicin idealisib iinotuzumab target iinotuzumab target iinotuzumab target iinotecan chemo iivosidenib target lapatinib target letrozole leuprolide london indonatinib target mercaptopurine methotrexate milosume neratinib target mitorycin milotinib chemo londatinic mercatinib target letrozole mercatinib target mitotane mitotane mitotane mitotane mitotane mitotane mitotane mercatinib target mercaptopurine chemo mitotane mercatinib target mitorece meratinib target mitorece meratinib target mercaptopurine chemo mitoxantrone melarabine chemo mitoxantrone neratinib target larget mercaptopurine chemo mitoxantrone chemo metatinib target chemo meratinib target chemo meratinib target chemo meratinib target mercaptopurine chemo methotrexate milotinib target nilotinib target		
erdafitinib target eribulin chemo erlotinib target etoposide chemo everolimus target exemestane endo fam-trastuzumab target fludarabine chemo fluorouracil chemo flutamide endo fulvestrant endo gemcitabine chemo gemtuzumab target goserelin endo hydroxyurea chemo ibrutinib target idarubicin chemo imatinib target interferon target irinotecan chemo ivosidenib target lapatinib target lapatinib target letrozole endo lorlatinib target letrozole metaosumic chemo mitotane endo mitoxanurone chemo mitotane neratinib target mitomycin mitotane neratinib target mitomycin mitotane neratinib target mitomycin chemo mitotane neratinib target mitomycin chemo mitotane neratinib target mitomycin chemo mitotane neratinib target chemo mitotane nendo mitoxantrone chemo neratinib target nilotinib target		
eribulin chemo erlotinib target etoposide chemo everolimus target exemestane endo fam-trastuzumab target fludarabine chemo fluorouracil chemo flutamide endo gemcitabine chemo gemtuzumab target goserelin endo hydroxyurea chemo idelalisib target interferon target interferon target ixabepilone chemo ixazomib target lapatinib target lapatinib target lenvatinib target mercaptopurine chemo lorlatinib target mercaptopurine chemo midostaurin target mitomycin chemo mitoxantrone chemo nelarabine chemo nelarabine chemo nelarabine chemo nelarabine chemo nelarabine chemo neratinib target nilotinib target		
erlotinib target etoposide chemo everolimus target exemestane endo fam-trastuzumab target fludarabine chemo fluorouracil chemo flutamide endo gemcitabine chemo gemtuzumab target goserelin endo hydroxyurea chemo ibrutinib target ifosfamide chemo imatinib target interferon target ixabepilone chemo ixazomib target lapatinib target lapatinib target lapatinib target lenvatinib target lenvatinib target letrozole endo lorlatinib target mitowaturone chemo mitotane midostaurin target mitowaturone nelarabine chemo mitotane neratinib target mitomycin chemo mitotane nelarabine chemo nelarabine chemo nelarabine chemo mitotane nelarabine chemo neratinib target nilotinib target		<del>- i</del>
etoposide chemo everolimus target exemestane endo fam-trastuzumab target fludarabine chemo fluorouracil chemo flutamide endo fulvestrant endo gemitzumab target goserelin endo hydroxyurea chemo ibrutinib target ifosfamide chemo imatinib target interferon target irinotecan chemo ivosidenib target lapatinib target lapatinib target larotrectinib target lenvatinib target letrozole endo lomustine chemo methotrexate chemo mitotane mitoxantrone nelarabine chemo nelarabine chemo micotanib target mitorycin chemo mitotane mitoxantrone nelarabine chemo micotanib target mitorycin chemo micotane chemo mitoxantrone nelarabine chemo metatinib target marget mitorycin chemo mitoxantrone nelarabine chemo neratinib target mitorycin chemo metatinib target mercaptopurine chemo mitoxantrone chemo nelarabine chemo nelarabine chemo neratinib target mitotinib target mitoget mitoxantrone chemo nelarabine chemo nelarabine chemo nelarabine chemo nelarabine chemo neratinib target nilotinib target nilotinib target nilotinib target nilotinib target nilotinib target nilotinib target		
everolimus target exemestane endo fam-trastuzumab target fludarabine chemo flutorouracil chemo flutamide endo fulvestrant endo gemcitabine chemo gemtuzumab target goserelin endo hydroxyurea chemo ibrutinib target idarubicin chemo idelalisib target ifosfamide chemo imatinib target interferon target irinotecan chemo ivosidenib target ixabepilone chemo ixazomib target larotrectinib target lenalidomide endo leuprolide endo lomustine chemo lorlatinib target endo lomustine chemo ivaiget letrozole endo lomustine chemo methotrexate chemo mitoxantrone chemo indosantrone chemo mitoxantrone chemo neratinib target mitoryein target mitoryein chemo neratinib target mitoryein chemo nelarabine chemo nelarabine chemo nelarabine chemo nelarabine chemo neratinib target nilotinib target nilotinib target nilotinib target nilotinib target		<del> </del>
exemestane endo fam-trastuzumab target fludarabine chemo fluorouracil chemo flutamide endo gemitabine chemo gemitabine chemo gemtuzumab target goserelin endo hydroxyurea chemo idelalisib target ifosfamide chemo imatinib target interferon target irinotecan chemo ivosidenib target lapatinib target lapatinib target lenvatinib target mercaptopurine chemo methotrexate chemo midostaurin target mitomycin chemo mitotane endo mitoxantrone chemo nelarabine chemo neratinib target		
fam-trastuzumab fludarabine fluorouracil fludarabine fluorouracil chemo flutamide endo fulvestrant gemcitabine gemcitabine gemtuzumab target goserelin endo hydroxyurea chemo ibrutinib target idarubicin idelalisib target ifosfamide inotuzumab target inotuzumab target inotuzumab target interferon ivosidenib target ixabepilone chemo ixazomib target lapatinib target lerozole leuprolide leurolide lomustine methotrexate midosyatrant mitomycin methore nelarabine neratinib target mercaptopurine methotrexate mitomycin mitotine neratinib target larget larget mercaptopurine nelarabine neratinib target mercaptopurine nelarabine neratinib target larget larget larget larget mercaptopurine methorexate midostaurin nelarabine neratinib target larget larget larget larget mercaptopurine chemo mitotane nelarabine neratinib target larget		Š
fludarabine fluorouracil flutamide flutamide fulvestrant gemcitabine gemcitabine gemtuzumab gemcitabine gemtuzumab target goserelin endo hydroxyurea chemo ibrutinib target iidarubicin idelalisib target iifosfamide iinotuzumab target iinotecan ivosidenib target ixabepilone ixazomib target lapatinib target lenalidomide leuprolide leurolide metotrexate mercaptopurine metotrexate mitoxantrone nelarabine neratinib funda funda endo gemcitabine chemo chemo chemo itarget itarget larget larget larget lendo lomustine chemo mitotane nelarabine neratinib target larget larget larget larget larget lendo lomustine chemo methotrexate mitomycin nelarabine neratinib target larget lar		
fluorouracil chemo flutamide endo fulvestrant endo gemcitabine chemo gemtuzumab target goserelin endo hydroxyurea chemo ibrutinib target idarubicin chemo imatinib target inotuzumab target inotuzumab target iniotuzumab target iniotuzumab target interferon target irinotecan chemo ixazomib target lapatinib target lapatinib target lenvatinib target letrozole endo lomustine chemo methotrexate chemo midostaurin target mitomycin chemo mitotane endo nelarabine neratinib target nilotinib target mitomycin chemo mitotane endo nelarabine chemo neratinib target nilotinib target nilotinib target nilotinib target		Š
flutamide endo fulvestrant endo gemcitabine chemo gemtuzumab target goserelin endo hydroxyurea chemo ibrutinib target idarubicin chemo idelalisib target iinotuzumab target iinotuzumab target iinotuzumab target iinotuzumab target iinotuzumab target iinotuzumab target iinotecan chemo iivosidenib target ixabepilone chemo ixazomib target lapatinib target larotrectinib target lenalidomide target lenvatinib target letrozole endo lomustine chemo methotrexate chemo mitotane endo mitoxantrone nelarabine neratinib target nilotinib target mercaptopurine chemo mitotane endo mitoxantrone chemo nelarabine neratinib target nilotinib target nilotinib target nilotinib target nilotinib target		
fulvestrant gemcitabine gemtuzumab gemtuzumab target goserelin hydroxyurea ibrutinib target idarubicin idelalisib ifosfamide imatinib itarget inotuzumab interferon ivosidenib itarget ixabepilone ixazomib target lapatinib target lenvatinib target letrozole leuprolide lomustine methotrexate mitomycin methotrexate mitoxantrone nelarabine neraatinib target target itarget chemo ch		
gemitzumab gemitzumab gemitzumab target goserelin hydroxyurea ibrutinib target idarubicin idelalisib target ifosfamide imatinib target inotuzumab target interferon ivosidenib target ixabepilone ixazomib target lapatinib target lenvatinib target letrozole leuprolide lomustine methotrexate mitomycin mitotane neratinib target target chemo chemo chemo lorlatinib target mercaptopurine methotrexate mitomycin methotinib target larget larget mercaptopurine neratinib target nilotinib target larget mercaptopurine chemo methotrexate mitomycin neratinib target larget larget mercaptopurine chemo methotexate mitomycin mitotane neratinib target nilotinib target larget larget larget mitomycin chemo neratinib target larget		
gemtuzumab goserelin endo hydroxyurea ibrutinib idarubicin idelalisib ifosfamide imatinib interferon ivosidenib ixapet lapatinib larget larotrectinib letrozole leuprolide lomustine lorlatinib itarget larotrexate mitomycin methotrexate mitotane methotrexate notatinib letrozole methotrexate mitotane methotrexate nilotinib target larote endo lomustine methotrexate mitotane nelarabine neratinib ltarget ltarget ltarget ltarget mercaptopurine methotrexate mitomycin methotinib ltarget ltarget ltarget ltarget mercaptopurine methotexate mitotane melarabine nelarabine neratinib target ltarget ltarget mercaptopurine chemo methotexate mitotane melo methotinib mitotane melarabine neratinib target ltarget nilotinib target ltarget nilotinib target nilotinib target nilotinib target nilotinib target nilotinib target nilotinib target nilotinib		
goserelin endo hydroxyurea chemo ibrutinib target idarubicin chemo idelalisib target ifosfamide chemo imatinib target inotuzumab target initerferon target irinotecan chemo ivosidenib target lapatinib target lapatinib target larotrectinib target lenvatinib target letrozole endo lomustine chemo lorlatinib target mercaptopurine methotrexate mitomycin mitotane mitoxantrone nelarabine chemo neratinib target mercaptopurine chemo mitoxantrone nelarabine chemo neratinib target nilotinib target nilotinib target mercaptopurine chemo mitoxantrone chemo neratinib target nilotinib target mercaptopurine chemo methotrexate chemo mitotane endo mitoxantrone chemo neratinib target nilotinib target nilotinib target nilotinib target nilotinib target		
hydroxyurea chemo ibrutinib target idarubicin chemo idelalisib target ifosfamide chemo imatinib target inotuzumab target interferon target irinotecan chemo ivosidenib target lapatinib target lapatinib target lenvatinib target lenvatinib target letrozole endo lomustine chemo methotrexate midostaurin target mitomycin chemo metarabine chemo motavantrone chemo indeed target motavantrone chemo motavantrone chemo metaraget mitomycin target mercaptopurine chemo metaraget mitomycin chemo metaraget mitomycin target marget mitomycin chemo metaraget mitomycin chemo metaraget mitomycin chemo metaraget mitomycin target mitomycin chemo metaraget mitomycin target mitomycin chemo metaraget mitomycin target mitomycin target mitomycin chemo metaraget mitomycin target mitomycin chemo metaraget mitomycin target	8	<del>- i</del>
ibrutinib idarubicin chemo idelalisib target ifosfamide chemo imatinib target inotuzumab target interferon target irinotecan ivosidenib target lapatinib target lapatinib target lenvatinib target letrozole leuprolide lomustine lorlatinib mercaptopurine methotrexate mitomycin mitotane neratinib target itarget itarget larget larget larget lenvatinib target lenvatinib target lenvatinib target lenvatinib target lenvatinib target lenvatinib target letrozole endo lomustine lorlatinib mercaptopurine methotrexate mitomycin chemo mitotane endo nelarabine neratinib target larget larget mitomycin chemo nelarabine neratinib target nilotinib target	0	
idarubicin  idelalisib  target  ifosfamide  chemo  imatinib  target  inotuzumab  interferon  ivosidenib  target  ixabepilone  lapatinib  larget  larotrectinib  lenalidomide  lenvatinib  target  letrozole  leuprolide  lomustine  lorlatinib  target  mercaptopurine  methotrexate  mitomycin  mitotane  nelarabine  neratinib  target  larget  chemo  chemo  chemo  mitotane  nelarabine  chemo  lorlatinib  target  chemo  nelarabine  chemo  neratinib  target  target  target  chemo  nelarabine  chemo  neratinib  target  target  nilotinib  target  target  marget  chemo  mitotane  nelarabine  chemo  neratinib  target  target  nilotinib  target  nilotinib  target  nilotinib  target  nilotinib  target  nilotinib  target  nilotinib		chemo
idelalisib ifosfamide chemo imatinib inotuzumab interferon interferon ivosidenib ixabepilone ixazomib lapatinib larget lenvatinib lenvatinib letrozole leuprolide lomustine lorlatinib mercaptopurine methotrexate mitomycin mitoxantrone nelarabine ifforte iffosfamide chemo itarget larget larget letrozole leuprolide lenvatinib larget letrozole methotrexate chemo mitoxantrone nelarabine neratinib larget larget chemo chemo neratinib larget letrozole chemo mitoxantrone chemo mitoxantrone nelarabine neratinib larget		<del>- i</del>
ifosfamide chemo imatinib target inotuzumab target interferon target irinotecan chemo ivosidenib target ixabepilone chemo ixazomib target lapatinib target larotrectinib target lenalidomide target letrozole endo lomustine chemo lorlatinib target mercaptopurine chemo mitotane endo mitoxantrone nelarabine imatevatinib target mercaptopurine chemo mitotane chemo neratinib target mercaptopurine chemo mitoxantrone chemo neratinib target mitomycin target mitomycin target mitomycin chemo methotrexate chemo mitoxantrone chemo methotinib target mitomycin target mitomycin target mitomycin target mitomycin target mitoxantrone chemo mitotane target mitotinib target mitotinib target mitotinib target		chemo
imatinib inotuzumab interferon interferon ivosidenib ivosidenib ixabepilone ixazomib lapatinib larget larotrectinib lenalidomide lenvatinib letrozole leuprolide lomustine lorlatinib methotrexate mitomycin mitotane melarabine neratinib itarget ltarget ltarget ltarget ltarget lenvatinib ltarget lendo lomustine lorlatinib ltarget lenvatinib ltarget lendo lorlatinib ltarget mercaptopurine methotrexate mitomycin mitotane melarabine neratinib ltarget ltarget mitorycin chemo mitotane melarabine neratinib ltarget nilotinib ltarget nilotinib ltarget nilotinib ltarget nilotinib ltarget nilotinib ltarget		<del>- i</del>
inotuzumab interferon interferon ivosidenib ivosidenib ixabepilone ixazomib lapatinib larget larotrectinib lenalidomide lenvatinib letrozole leuprolide lomustine lorlatinib mercaptopurine methotrexate mitomycin mitotane melarabine neratinib itarget ltarget ltarget ltarget lenvatinib ltarget lenvatinib ltarget lenvatinib ltarget lenvatinib ltarget endo lomustine chemo methotexate mitomycin mitotane mitoxantrone nelarabine neratinib ltarget		chemo
interferon target irinotecan chemo ivosidenib target ixabepilone chemo ixazomib target lapatinib target larotrectinib target lenalidomide target lenvatinib target letrozole endo lomustine chemo lorlatinib target mercaptopurine chemo methotrexate midostaurin target mitomycin chemo nelarabine chemo neratinib target irinotecan chemo methotecan chemo mitotane endo mitoxantrone chemo nelarabine chemo neratinib target mitomycin target mitomycin chemo neratinib target nilotinib target		target
irinotecan ivosidenib target ixabepilone chemo ixazomib target lapatinib target larotrectinib target lenalidomide target lenvatinib target letrozole leuprolide lomustine lorlatinib target mercaptopurine methotrexate midostaurin mitotane neratinib target nilotinib target chemo chemo chemo metaspet mercaptopurine chemo mitotane mitotane neratinib target mitarget		target
ivosidenibtargetixabepilonechemoixazomibtargetlapatinibtargetlarotrectinibtargetlenalidomidetargetlenvatinibtargetletrozoleendoleuprolideendolomustinechemolorlatinibtargetmercaptopurinechemomethotrexatechemomidostaurintargetmitomycinchemomitotaneendonelarabinechemoneratinibtargetnilotinibtarget		<del>- i</del>
ixabepilone ixazomib target lapatinib target larotrectinib target lenalidomide target lenvatinib target letrozole leuprolide lomustine lorlatinib target mercaptopurine methotrexate mitomycin mitotane neratinib ixazet nilotinib target chemo chemo methotexate mitosantrone nelarabine neratinib target mitarget		chemo
ixazomib target lapatinib target larotrectinib target lenalidomide target lenvatinib target letrozole endo leuprolide endo lomustine chemo lorlatinib target mercaptopurine chemo methotrexate chemo mitostaurin target mitomycin chemo mitoxantrone endo neratinib target nilotinib target mitorycin chemo mitoxantrone chemo neratinib target nilotinib target nilotinib target		target
lapatinibtargetlarotrectinibtargetlenalidomidetargetlenvatinibtargetletrozoleendoleuprolideendolomustinechemolorlatinibtargetmercaptopurinechemomethotrexatechemomidostaurintargetmitomycinchemomitotaneendomitoxantronechemonelarabinechemoneratinibtargetnilotinibtarget	ixabepilone	chemo
larotrectinib lenalidomide lenalidomide target lenvatinib target letrozole letrozole leuprolide lomustine lorlatinib target mercaptopurine methotrexate midostaurin mitomycin mitotane melarabine neratinib target mercaptopurine chemo mitotane mitotane mitotane neratinib target mitomycin target mitomycin target mitomycin mitotane target		
lenalidomide target lenvatinib target letrozole endo leuprolide endo lomustine chemo lorlatinib target mercaptopurine chemo methotrexate chemo midostaurin target mitomycin chemo mitotane endo mitoxantrone chemo neratinib target nilotinib target mitorget chemo mitotane endo mitoxantrone chemo neratinib target nilotinib target		target
lenvatinib letrozole leuprolide leuprolide lomustine lorlatinib target mercaptopurine methotrexate midostaurin mitomycin mitotane melarabine neratinib target chemo methotexate chemo mitotane mitoxantrone nelarabine neratinib target mitorycin target mitoxantrone nelarabine neratinib target mitoxantrone nelarabine neratinib target milotinib		<del>- i</del>
letrozole       endo         leuprolide       endo         lomustine       chemo         lorlatinib       target         mercaptopurine       chemo         methotrexate       chemo         midostaurin       target         mitomycin       chemo         mitotane       endo         mitoxantrone       chemo         nelarabine       chemo         neratinib       target         nilotinib       target		target
leuprolide       endo         lomustine       chemo         lorlatinib       target         mercaptopurine       chemo         methotrexate       chemo         midostaurin       target         mitomycin       chemo         mitotane       endo         mitoxantrone       chemo         nelarabine       chemo         neratinib       target         nilotinib       target		
lomustine       chemo         lorlatinib       target         mercaptopurine       chemo         methotrexate       chemo         midostaurin       target         mitomycin       chemo         mitotane       endo         mitoxantrone       chemo         nelarabine       chemo         neratinib       target         nilotinib       target		endo
lorlatinib target mercaptopurine chemo methotrexate chemo midostaurin target mitomycin chemo mitotane endo mitoxantrone chemo nelarabine chemo neratinib target nilotinib target	leuprolide	endo
mercaptopurine chemo methotrexate chemo midostaurin target mitomycin chemo mitotane endo mitoxantrone chemo nelarabine chemo neratinib target nilotinib target		chemo
methotrexate       chemo         midostaurin       target         mitomycin       chemo         mitotane       endo         mitoxantrone       chemo         nelarabine       chemo         neratinib       target         nilotinib       target	lorlatinib	target
methotrexatechemomidostaurintargetmitomycinchemomitotaneendomitoxantronechemonelarabinechemoneratinibtargetnilotinibtarget	mercaptopurine	chemo
mitomycinchemomitotaneendomitoxantronechemonelarabinechemoneratinibtargetnilotinibtarget		chemo
mitotane endo mitoxantrone chemo nelarabine chemo neratinib target nilotinib target	midostaurin	target
mitotaneendomitoxantronechemonelarabinechemoneratinibtargetnilotinibtarget	mitomycin	chemo
nelarabinechemoneratinibtargetnilotinibtarget		endo
neratinib target nilotinib target	mitoxantrone	chemo
nilotinib target	nelarabine	chemo
	neratinib	target
niraparib target	nilotinib	target
	niraparib	target

nivolumab	immuno
obinutuzumab	target
ofatumumab	target
olaparib	target
olaratumab	target
osimertinib	target
oxaliplatin	chemo
•	chemo
paclitaxel	
palbociclib	target
panitumumab	target
panobinostat	target
pazopanib	target
pegaspargase	chemo
peginterferon	target
pembrolizumab	immuno
pemetrexed	chemo
pertuzumab	target
polatuzumab	target
pomalidomide	target
ponatinib	target
procarbazine	chemo
ramucirumab	target
regorafenib	target
ribociclib	target
rituximab	target
romidepsin	target
ruxolitinib	target
sacituzumab	target
selpercatinib	target
sorafenib	target
sunitinib	target
tafasitamab-cxix	target
talazoparib	target
tamoxifen	endo
temozolomide	chemo
temsirolimus	target
thiotepa	chemo
topotecan	chemo
trabectedin	chemo
trametinib	target
trastuzumab	target
trastuzumab-anns	target
tretinoin	target
trifluridine/tipiracil	chemo
triptorelin	endo
tucatinib	target
vemurafenib	target
venetoclax	target
vinblastine	chemo
vincristine	chemo
vinorelbine	chemo
vismodegib	target
vorinostat	target
· JIIIJJuut	500

alemtuzumab	target
capmatinib	target
daratumumab-hyaluronidase-fihj	target
decitabine/cedazuridine	target
enfortumab	target
gilteritinib	target
ipilimumab	immuno
lurbinectedin	chemo
mechlorethamine	chemo
melphalan	chemo
pemigatinib	target
pentostatin	chemo
pertuzumab-trastuzumab-hy-zzxf	target
ripretinib	target
rucaparib	target
siltuximab	target
sonidegib	target
valrubicin	chemo
vandetanib	target
gefitinib	target
nilutamide	endo
thioguanine	chemo
toremifene	endo

eTable 2. Cumulative Incidence of VTE at 6 and 12 Months by Diagnosis Year

Diagnosis year	N (%)	6-month	12-month
Diagnosis year	11 (70)	CI VTE	CI VTE
2006	28,121 (6.5%)	3.0%	4.2%
2007	30,174 (6.9%)	3.0%	4.1%
2008	29,954 (6.9%)	3.4%	4.7%
2009	30,405 (7.0%)	3.0%	4.2%
2010	30,050 (6.9%)	3.4%	4.7%
2011	30,393 (7.0%)	3.1%	4.6%
2012	29,696 (6.8%)	3.1%	4.5%
2013	29,068 (6.7%)	3.2%	4.4%
2014	29,165 (6.7%)	3.5%	5.0%
2015	29,939 (6.9%)	3.4%	4.6%
2016	29,654 (6.8%)	3.3%	4.6%
2017	30,325 (7.0%)	3.3%	4.6%
2018	27,931 (6.4%)	3.2%	4.5%
2019	24,057 (5.5%)	3.2%	4.7%
2020	16,850 (3.9%)	3.6%	5.0%
2021	8,421 (1.9%)	3.5%	4.7%

Abbreviations: VTE, venous thromboembolism; CI, cumulative incidence

eTable 3. Cumulative Incidence of VTE at 1 Year by Cancer Type (A) Among all patients (n= 434,203)

Compan T	N	CI VTE		CI PE/LE-DVT	
Cancer Type	IN	6 months	12 months	6 months	12 months
ALL	193	16.2%	18.6%	10.0%	11.8%
pancreas	8,925	9.8%	12.1%	8.4%	10.3%
brain	2,485	9.0%	11.1%	8.2%	10.1%
bile & gallbladder	2,546	6.7%	9.1%	5.7%	8.1%
aggressive NHL	5,351	8.9%	11.0%	6.3%	7.9%
upper GI	13,399	7.6%	10.0%	5.8%	7.7%
myeloma	6,470	4.9%	7.7%	3.9%	6.4%
Hodgkin lymphoma	1,129	6.7%	9.5%	4.3%	6.3%
lung	7,5441	5.2%	6.9%	4.2%	5.6%
lower GI	29,580	4.7%	6.7%	3.7%	5.3%
sarcoma	3,017	4.4%	6.2%	3.4%	5.0%
bladder	15,040	3.8%	5.8%	3.1%	4.8%
gynecologic	1,246	3.1%	4.9%	3.0%	4.7%
miscellaneous solid	13,763	4.7%	6.0%	3.7%	4.7%
testicular	1,006	4.0%	5.3%	3.0%	3.6%
neuroendocrine	6,831	3.2%	4.3%	2.7%	3.6%
kidney	18,315	3.0%	3.9%	2.6%	3.5%
AML	2,657	6.4%	7.3%	3.1%	3.6%
indolent NHL	8,987	3.3%	4.5%	2.3%	3.2%
head & neck	25,486	3.0%	4.1%	2.0%	2.6%
breast	5,075	1.9%	3.4%	1.2%	2.4%
liver	17,406	1.8%	2.7%	1.6%	2.3%
MDS	4,897	1.6%	2.7%	1.1%	2.0%
CLL	6,486	1.1%	2.0%	0.9%	1.6%
CML	3,840	1.0%	2.1%	0.8%	1.6%
melanoma	16,702	0.9%	1.7%	0.8%	1.4%
prostate	133,085	0.9%	1.5%	0.8%	1.3%
thyroid	4,845	1.0%	1.6%	0.8%	1.2%

(B) Among patients treated with systemic therapy within first 90 days (n= 118,731)

C T N		CI VTE		CI PE/LE-DVT	
Cancer Type	N	6 months	12 months	6 months	12 months
ALL	147	20.5%	22.7%	12.3%	13.8%
pancreas	3611	13.4%	17.3%	11.3%	14.7%
brain	1351	10.9%	13.7%	10.3%	12.8%
bile & gallbladder	696	10.6%	14.4%	9.1%	12.8%
aggressive NHL	3819	10.9%	13.2%	7.7%	9.5%
upper GI	6190	10.5%	13.9%	7.7%	10.4%
myeloma	3594	5.9%	9.4%	4.9%	7.9%
Hodgkin lymphoma	788	8.1%	10.6%	5.1%	7.0%
lung	24938	7.9%	10.3%	6.2%	8.2%
lower GI	8737	6.8%	9.9%	5.2%	7.7%
sarcoma	320	11.1%	12.5%	6.3%	7.0%
bladder	4667	5.4%	7.7%	4.3%	6.2%
gynecologic	154	12.5%	15.3%	11.1%	13.9%
miscellaneous solid	3598	7.8%	9.9%	5.4%	7.0%
testicular	264	11.3%	12.7%	8.1%	8.6%
neuroendocrine	1216	8.0%	10.0%	6.2%	7.8%
kidney	1541	7.8%	9.6%	6.8%	8.2%
AML	1564	8.8%	9.7%	4.1%	4.7%
indolent NHL	3609	5.4%	6.9%	3.5%	4.6%
head & neck	9111	4.5%	5.9%	2.7%	3.5%
breast	1971	3.1%	4.7%	1.9%	3.0%
liver	4839	2.5%	3.7%	2.2%	3.2%
MDS	1227	2.9%	4.5%	1.9%	3.2%
CLL	769	3.6%	4.5%	2.5%	3.3%
CML	2635	0.9%	1.9%	0.7%	1.4%
melanoma	1332	2.3%	3.2%	1.9%	2.9%
prostate	25931	1.1%	2.1%	1.0%	1.9%
thyroid	112	3.6%	6.7%	1.8%	3.9%

Abbreviations: CI, cumulative incidence; VTE, venous

thromboembolism; PE/LE-DVT, pulmonary embolism / lower-extremity deep venous thrombosis; ALL, acute lymphocytic leukemia; NHL, non-Hodgkin lymphoma; GI, gastrointestinal; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia

eTable 4. Cumulative Incidence of VTE by Cancer Stage

Cancer Type	Stage I-II	Stage III-IV
ALL	29 (13.8%)	164 (19.3%)
pancreas	3123 (9.9%)	5802 (13.2%)
brain	2437 (11.0%)	48 (14.7%)
bile & gallbladder	1362 (7.7%)	1184 (10.8%)
aggressive NHL	2137 (9.4%)	3214 (12.1%)
upper GI	5652 (8.4%)	7747 (11.2%)
myeloma	0 (0.0%)	6470 (7.7%)
Hodgkin lymphoma	524 (10.2%)	605 (8.9%)
lung	29152 (4.6%)	46289 (8.2%)
lower GI	17279 (4.8%)	12301 (9.0%)
sarcoma	2303 (5.0%)	714 (9.7%)
bladder	12411 (4.0%)	2629 (13.6%)
gynecologic	951 (2.6%)	295 (12.1%)
miscellaneous solid	11685 (5.7%)	2078 (7.5%)
testicular	918 (3.6%)	88 (22.0%)
neuroendocrine	4579 (3.4%)	2252 (6.2%)
kidney	13747 (2.6%)	4568 (7.9%)
AML	0 (0.0%)	2657 (7.3%)
indolent NHL	4052 (3.1%)	4935 (5.6%)
head & neck	10655 (2.5%)	14831 (5.2%)
breast	4309 (2.9%)	766 (6.3%)
liver	12158 (2.1%)	5248 (4.0%)
MDS	0 (0.0%)	4897 (2.7%)
CLL	951 (1.4%)	5535 (2.1%)
CML	0 (0.0%)	3840 (2.1%)
melanoma	14825 (1.2%)	1877 (4.8%)
prostate	112538 (1.3%)	20547 (2.8%)
thyroid	3760 (1.2%)	1085 (2.9%)

Abbreviations: VTE, venous thromboembolism; ALL, acute lymphocytic leukemia; NHL, non-Hodgkin lymphoma; GI, gastrointestinal; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia

eTable 5. Cumulative Incidence of VTE by Race and Ethnicity<sup>a</sup>

Cancer Type	Hispanic	Non-Hispanic API	Non-Hispanic Black	Non-Hispanic White
ALL	15 (0.0%)	0 (0.0%)	17 (0.0%)	154 (17.5%)
pancreas	417 (11.1%)	166 (10.1%)	1,720 (16.2%)	6,508 (11.2%)
brain	119 (13.0%)	42 (0.0%)	274 (14.4%)	2,019 (10.7%)
bile & gallbladder	195 (8.9%)	47 (0.0%)	455 (11.6%)	1,819 (8.7%)
aggressive NHL	343 (9.7%)	127 (13.7%)	715 (12.8%)	4,113 (10.8%)
upper GI	700 (10.0%)	241 (7.5%)	2,238 (11.0%)	10,074 (9.8%)
myeloma	344 (7.3%)	132 (4.2%)	2,014 (7.9%)	3,903 (7.8%)
Hodgkin lymphoma	77 (0.0%)	23 (0.0%)	208 (6.7%)	809 (11.1%)
lung	1,704 (9.0%)	1,112 (5.8%)	12,054 (9.0%)	59,860 (6.4%)
lower GI	1,791 (7.1%)	611 (5.3%)	5,388 (8.4%)	21,505 (6.2%)
sarcoma	175 (6.9%)	59 (0.0%)	516 (9.0%)	2,241 (5.6%)
bladder	517 (5.3%)	190 (6.1%)	1,416 (7.5%)	12,779 (5.6%)
gynecologic	56 (0.0%)	39 (0.0%)	248 (3.1%)	888 (5.9%)
miscellaneous solid	664 (6.7%)	228 (3.7%)	2,226 (7.3%)	10,516 (5.7%)
testicular	105 (4.5%)	22 (0.0%)	64 (0.0%)	807 (5.6%)
neuroendocrine	355 (5.3%)	113 (5.3%)	1,519 (4.2%)	4,779 (4.3%)
kidney	1,157 (3.6%)	382 (5.2%)	3,700 (3.2%)	12,898 (4.1%)
AML	114 (10.7%)	53 (0.0%)	334 (7.2%)	2,130 (6.9%)
indolent NHL	467 (5.2%)	152 (4.1%)	1,134 (4.8%)	7,152 (4.4%)
head & neck	962 (5.0%)	377 (5.1%)	3,885 (4.8%)	20,006 (4.0%)
breast	241 (2.3%)	145 (0.8%)	1,411 (3.9%)	3,225 (3.4%)
liver	1,588 (3.1%)	381 (1.7%)	4,281 (2.5%)	10,984 (2.7%)
MDS	206 (3.1%)	75 (0.0%)	532 (3.5%)	4,041 (2.6%)
CLL	197 (2.4%)	88 (0.0%)	743 (2.4%)	5,396 (2.0%)
CML	177 (0.6%)	68 (0.0%)	614 (2.0%)	2,944 (2.3%)
melanoma	194 (3.7%)	168 (1.7%)	119 (4.8%)	16,094 (1.6%)
prostate	6,952 (1.1%)	2,221 (0.9%)	40,853 (1.6%)	81,932 (1.5%)
thyroid	361 (1.3%)	152 (2.3%)	693 (1.6%)	3,581 (1.5%)

<sup>a</sup>Race/ethnicity groups with fewer than 100 events by specific cancer type were excluded from representation. Abbreviations: VTE, venous thromboembolism; API, Asian Pacific Islander; ALL, acute lymphocytic leukemia; NHL, non-Hodgkin lymphoma; GI, gastrointestinal; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia

eTable 6. Multivariable Cox Regression Analysis for Association With Overall Mortality


e l'able 6. Multivariable Cox Regressio	
Variables	Overall VTE
A 22 200 10 200 in 200 200	HR (95% CI) 1.47 (1.47 - 1.48)
Age, every 10-year increase	`
Male sex	1.24 (1.21 - 1.28)
Race/Ethnicity	D.C
Non-Hispanic White	Ref.
Non-Hispanic Black	0.92 (0.91 - 0.93)
Hispanic ADI	0.81 (0.79 - 0.82)
Non-Hispanic API	0.91 (0.88 - 0.94)
Rurality Urban	Ref.
Rural	
	0.97 (0.96 - 0.98)
Unknown	1.04 (1.00 - 1.08)
Region	D of
Continental	Ref.
Southeast	0.97 (0.95 - 0.98)
Midwest	0.96 (0.95 - 0.98)
North Atlantic	0.93 (0.92 - 0.95)
Pacific National ADI	0.99 (0.98 - 1.01)
	Ref.
0-25%	
26-50%	1.03 (1.01 - 1.04)
51-75%	1.06 (1.04 - 1.07)
76-100%	1.15 (1.13 - 1.16)
Unknown	1.11 (1.07 - 1.14)
NCI-CI	1.50 (1.49 - 1.51)
Year of diagnosis Khorana Score Predictors	0.98 (0.98 - 0.98)
_	0.02 (0.02 0.04)
BMI $\ge 35 \text{ kg/m}^2$ WBC $> 11 \times 10^9/\text{L}$	0.93 (0.92 - 0.94)
	1.28 (1.27 - 1.30)
$\begin{array}{c} \text{Hgb} < 10 \text{ g/dL} \\ \text{Platelet} \ge 350 \times 10^9 \text{/L} \end{array}$	1.37 (1.35 - 1.39) 1.29 (1.27 - 1.31)
Additional VTE predictors	1.29 (1.27 - 1.31)
History of VTE	1.11 (1.09 - 1.13)
History of paralysis	1.09 (1.05 - 1.14)
Recent hospitalization (90d)	1.45 (1.43 - 1.46)
Baseline Anticoagulant	1.43 (1.43 - 1.40)
None	Ref.
Warfarin	1.07 (1.05 - 1.09)
LMWH	0.96 (0.92 - 1.00)
DOAC	0.96 (0.93 - 1.00)
Baseline Antiplatelet	0.70 (0.73 - 1.00)
None	Ref.
Aspirin	1.05 (1.04 - 1.06)
P2Y12 inhibitor	1.03 (1.01 - 1.05)
Aspirin + P2Y12 inhibitor	0.97 (0.91 - 1.03)
Other	1.09 (1.04 - 1.14)
Cancer Site	
Prostate	Ref.
CML	0.50 (0.48 - 0.53)
CLL	0.50 (0.48 - 0.52)
Thyroid	0.87 (0.82 - 0.92)
Indolent NHL	1.01 (0.97 - 1.04)
1	(/

<sup>© 2023</sup> Martens KL et al. JAMA Network Open.

Multiple myeloma	1.01 (0.98 - 1.05)
Hodgkin lymphoma	1.06 (0.97 - 1.16)
MDS	1.11 (1.07 - 1.15)
Testicular	1.24 (1.05 - 1.45)
Aggressive NHL	1.51 (1.45 - 1.56)
Melanoma	1.67 (1.63 - 1.72)
Breast	1.72 (1.63 - 1.82)
Head & neck	1.95 (1.91 - 2.00)
Kidney	1.97 (1.92 - 2.02)
Lower GI	2.00 (1.96 - 2.04)
	· · · · · · · · · · · · · · · · · · ·
Neuroendocrine	2.08 (2.00 - 2.15)
Gynecologic	2.27 (2.05 - 2.51)
Sarcoma	2.45 (2.33 - 2.57)
ALL	2.54 (2.17 - 2.96)
AML	2.84 (2.72 - 2.97)
Bladder	2.86 (2.79 - 2.93)
Miscellaneous solid	3.97 (3.87 - 4.07)
Lung	5.08 (5.00 - 5.16)
Upper GI	5.52 (5.40 - 5.65)
Bile & gallbladder	6.32 (6.05 - 6.61)
Liver	7.08 (6.92 - 7.23)
Brain	8.09 (7.73 - 8.48)
Pancreas	10.05 (9.79 - 10.31)
Cancer Stage	
Stage I	Ref.
Stage II	1.58 (1.56 - 1.61)
Stage III	2.18 (2.15 - 2.21)
Stage IV	5.03 (4.97 - 5.10)
Unknown	2.15 (2.11 - 2.18)
First-line Systemic Therapy within 3	
months <sup>a</sup>	
None	Ref.
Chemotherapy+	0.89 (0.88 - 0.90)
Immune checkpoint inhibitor+	0.80 (0.74 - 0.86)
Targeted therapy+	0.94 (0.92 - 0.96)
Endocrine therapy	1.32 (1.29 - 1.35)


Abbreviations: VTE, venous thromboembolism; HR, hazard ratio; CI, confidence interval; API, Asian Pacific Islander; ADI, area deprivation index; BMI, body mass index; WBC, white blood cell; Hgb, hemoglobin; NCI-CI, National Cancer Institute comorbidity index; LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; GI, gastrointestinal; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia aFirst-line systemic therapy was treated as a time-varying covariate in the analysis

eFigure 1. Consort Diagram




Patient linkage, data harmonization, cohort exclusion, and variable extraction are described in detail in data supplemental Method 1.

eFigure 2. Cumulative Incidence of VTE at 1 Year by Cancer Stage



eFigure 3: Cumulative incidence of VTE at 1-year by cancer type and race/ethnicity<sup>a</sup>



<sup>a</sup>Race/ethnicity groups with fewer than 100 events by specific cancer type were excluded from representation. Abbreviations: ALL, acute lymphocytic leukemia; NHL, non-Hodgkin lymphoma; GI, gastrointestinal; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; NHW, Non-Hispanic White; NHB, Non-Hispanic Black, API, Asian Pacific Islander